Stratasys unveils new medical 3D printer designed for anatomical models, surgical guides and medical tooling

281
Stratasys medical J5 campaign

Additive manufacturing giant Stratasys Ltd. has introduced a medical 3D printer with multiple materials and multi-colour capabilities that enables users to create highly detailed 3D anatomical models and drilling and cutting guides with approved third-party 510k-cleared segmentation software.

The Stratasys J5 MediJet 3D printer, which companies multiple applications in one system, is the newest addition to the Stratasys J5 Series of printers, along with the J5 DentaJet and J55.

In operation, it features a patented rotating build platform with a fixed print head designed to maximise reliability and simplify maintenance.

Compared to other 3D printers, the MediJet 3D printer is up to 30% faster, along with a simple workflow that includes automatic build tray arrangement, corrections and support for the latest 3MF file format for simplifying connectivity to third-party segmentation and design software.

Stratasys’ Healthcare Vice President Osnat Philipp said the new all-in-one printer supports DraftWhite material for affordable single-material applications, along with a full array of new flexible, rigid colour, and transparent materials.

According to him, the multi-materials capabilities support a broad range of medical modeling applications in one office-friendly platform, which reduces outsourcing costs or the need for multiple printers.

“For small to midsized hospitals, we’re enabling access to models and guides with a medical-specific 3D printer that is office-friendly and affordable, while ensuring sterilization is easy so you can bring models right into the operating room with you,” Mr Philipp continued.

“We also believe the J5 MediJet printer can help medical device companies bring new innovations to market faster by providing models for benchmark testing of medical devices and for product demonstrations with models showing the actual pathologies the devices are meant to treat.”

Image credit: https://investors.stratasys.com/
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments